{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T16:07:58Z","timestamp":1768579678361,"version":"3.49.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"French Cooperative Thoracic Intergroup"},{"name":"Institut National du Cancer"},{"name":"AstraZenaca"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.lungcan.2020.11.008","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T11:20:34Z","timestamp":1605266434000},"page":"69-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project"],"prefix":"10.1016","volume":"151","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0572-8426","authenticated-orcid":false,"given":"H.","family":"Blons","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-B.","family":"Oudart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0305-0850","authenticated-orcid":false,"given":"J.-P.","family":"Merlio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Debieuvre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"de Fraipont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Audigier-Valette","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Escande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Hominal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7865-060X","authenticated-orcid":false,"given":"P.\u2010P.","family":"Bringuier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Fraboulet-Moreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4848-1232","authenticated-orcid":false,"given":"L.","family":"Ouafik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Moro-Sibilot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Lemoine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Langlais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Missy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Morin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.-J.","family":"Souquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Barlesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Cadranel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Beau\u2010Faller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.lungcan.2020.11.008_bib0005","first-page":"947","article-title":"Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2020.11.008_bib0010","first-page":"121","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol."},{"issue":"25","key":"10.1016\/j.lungcan.2020.11.008_bib0015","first-page":"2380","article-title":"Gefitinib or chemotherapy for non\u2013small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.lungcan.2020.11.008_bib0020","first-page":"735","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2020.11.008_bib0025","article-title":"EGFR mutation, smoking, and gender in advanced lung adenocarcinoma","author":"Tseng","year":"2017","journal-title":"Oncotarget [Internet]"},{"issue":"2","key":"10.1016\/j.lungcan.2020.11.008_bib0030","first-page":"144","article-title":"Impact of smoking status on EGFR-TKI efficacy for advanced non\u2013small-cell lung cancer in EGFR mutants: a meta-analysis","volume":"16","author":"Zhang","year":"2015","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2020.11.008_bib0035","article-title":"Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study","author":"Kim","year":"2018","journal-title":"Bmc Cancer [Internet]"},{"issue":"12","key":"10.1016\/j.lungcan.2020.11.008_bib0040","first-page":"1693","article-title":"Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers","volume":"49","author":"Blakely","year":"2017","journal-title":"Nat. Genet."},{"issue":"6","key":"10.1016\/j.lungcan.2020.11.008_bib0045","first-page":"596","article-title":"Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies","volume":"7","author":"Jordan","year":"2017","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.lungcan.2020.11.008_bib0050","first-page":"637","article-title":"Tumor clonality and resistance mechanisms in EGFR mutation-positive non-small-cell lung cancer: implications for therapeutic sequencing","volume":"15","author":"Kohsaka","year":"2019","journal-title":"Future Oncol."},{"key":"10.1016\/j.lungcan.2020.11.008_bib0055","article-title":"Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing","author":"Nahar","year":"2018","journal-title":"Nat. Commun. [Internet]."},{"key":"10.1016\/j.lungcan.2020.11.008_bib0060","first-page":"725","article-title":"Elisa Giovannetti & Marcello Tiseo Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"387","key":"10.1016\/j.lungcan.2020.11.008_bib0065","first-page":"1415","article-title":"Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)","volume":"2","author":"Barlesi","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2020.11.008_bib0070","first-page":"304","article-title":"Concurrent driver gene mutations as negative predictive factors in epidermal growth factor receptor-positive non-small cell lung cancer","volume":"42","author":"Chen","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.lungcan.2020.11.008_bib0075","first-page":"17","article-title":"Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: correlation with clinical outcomes","volume":"106","author":"VanderLaan","year":"2017","journal-title":"Lung Cancer"},{"issue":"7511","key":"10.1016\/j.lungcan.2020.11.008_bib0080","first-page":"543","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","author":"The Cancer Genome Atlas Research Network","year":"2014","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.lungcan.2020.11.008_bib0085","first-page":"606","article-title":"K-ras mutation subtypes in NSCLC and associated co-occuring mutations in other oncogenic pathways","volume":"14","author":"Scheffler","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2020.11.008_bib0090","article-title":"Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations","author":"Ruiz-Cordero","year":"2020","journal-title":"BMC Cancer [Internet]"},{"issue":"3","key":"10.1016\/j.lungcan.2020.11.008_bib0095","first-page":"199","article-title":"The prognostic impact of TP53 comutation in EGFR mutant lung cancer patients: a systematic review and meta-analysis","volume":"131","author":"Zhang","year":"2019","journal-title":"Postgrad. Med."},{"issue":"October","key":"10.1016\/j.lungcan.2020.11.008_bib0100","first-page":"vi426","article-title":"P53 non-disruptive mutation is a negative predictive factor in EGFR M+ NSCLC treated with TKI","volume":"27","author":"Griesinger","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2020.11.008_bib0105","first-page":"5665","article-title":"Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC","volume":"11","author":"Hou","year":"2019","journal-title":"Cancer Manage. Res."},{"issue":"13","key":"10.1016\/j.lungcan.2020.11.008_bib0110","first-page":"3108","article-title":"Concurrent alterations in EGFR-mutant lung cancers associated with resistance to EGFR kinase inhibitors and characterization of MTOR as a mediator of resistance","volume":"24","author":"Yu","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.lungcan.2020.11.008_bib0115","first-page":"3233","article-title":"Reduced expression levels of PTEN are associated with decreased sensitivity of HCC827 cells to icotinib","volume":"13","author":"Zhai","year":"2017","journal-title":"Oncol. Lett."},{"issue":"18","key":"10.1016\/j.lungcan.2020.11.008_bib0120","first-page":"2812","article-title":"Loss of PTEN\/MMAC1\/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors","volume":"22","author":"Bianco","year":"2003","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.lungcan.2020.11.008_bib0125","first-page":"3256","article-title":"PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of akt and EGFR","volume":"69","author":"Sos","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.lungcan.2020.11.008_bib0130","first-page":"1736","article-title":"HeoMechanisms of acquired resistance to AZD9291A mutation-selective, irreversible EGFR inhibitor","volume":"10","author":"Kim","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2020.11.008_bib0135","first-page":"444","article-title":"Enhanced gefitinib-induced repression of the epidermal growth factor receptor pathway by ataxia telangiectasia-mutated kinase inhibition in non-small-cell lung cancer cells","volume":"107","author":"Misumi","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.lungcan.2020.11.008_bib0140","article-title":"ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer","author":"Gei\u00dfler","year":"2017","journal-title":"Oncotarget [Internet]"},{"issue":"4","key":"10.1016\/j.lungcan.2020.11.008_bib0145","first-page":"278","article-title":"EGFR -mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes","volume":"37","author":"Marcoux","year":"2019","journal-title":"J. Clin. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220306838?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220306838?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:44:14Z","timestamp":1759236254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500220306838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":29,"alternative-id":["S0169500220306838"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.11.008","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}